<DOC>
	<DOC>NCT01047007</DOC>
	<brief_summary>The study evaluates safety of MK1775 in monotherapy, and in combination with 5-FU alone or with 5-FU/CDDP in Japanese patients with solid tumor</brief_summary>
	<brief_title>A Dose Escalation Study of MK1775 in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005)</brief_title>
	<detailed_description />
	<mesh_term>Fluorouracil</mesh_term>
	<criteria>Parts 1 and 2A: Patient must have a histologically or cytologically confirmed locally advanced or metastatic solid tumor failed to respond to standard therapy, progressed despite standard therapy, or for which standard therapy does not exist Parts 2B and 3: Patient must have a histologically or cytologically confirmed locally advanced or metastatic esophageal, head and neck, or gastric cancer, and be a candidate of 5Fluorouracil and Cisplatin regimen defined in this study Patient must have performance status of 0 or 1 on the ECOG Performance Scale Patient who has had chemotherapy, radiotherapy, or biological therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to the first dose of study drug or who has not recovered from adverse events due to agents administered more than 4 weeks earlier Patient with a known primary central nervous system tumor Patient has known hypersensitivity to any of the components of the combination study therapy or its analogs Patient is receiving "alternative" cancer medications such as plantderived products and their analogs with antitumor activity within 1 week prior to entering the study. Patient must not have prior radiation therapy to more than 30% of the bone marrow and must have recovered for at least 3 weeks from the hematologic toxicity of prior radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>Head and Neck Cancer</keyword>
	<keyword>Esophageal Cancer</keyword>
	<keyword>Gastric Cancer</keyword>
</DOC>